124 related articles for article (PubMed ID: 38911744)
1. Vanillin-Isatin Hybrid-Induced MARK4 Inhibition As a Promising Therapeutic Strategy against Hepatocellular Carcinoma.
Ahmed S; Queen A; Irfan I; Siddiqui MN; Abdulhameed Almuqdadi HT; Setia N; Ansari J; Hussain A; Hassan MI; Abid M
ACS Omega; 2024 Jun; 9(24):25945-25959. PubMed ID: 38911744
[TBL] [Abstract][Full Text] [Related]
2. Design and development of Isatin-triazole hydrazones as potential inhibitors of microtubule affinity-regulating kinase 4 for the therapeutic management of cell proliferation and metastasis.
Aneja B; Khan NS; Khan P; Queen A; Hussain A; Rehman MT; Alajmi MF; El-Seedi HR; Ali S; Hassan MI; Abid M
Eur J Med Chem; 2019 Feb; 163():840-852. PubMed ID: 30579124
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies.
Khan P; Rahman S; Queen A; Manzoor S; Naz F; Hasan GM; Luqman S; Kim J; Islam A; Ahmad F; Hassan MI
Sci Rep; 2017 Aug; 7(1):9470. PubMed ID: 28842631
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.
Naz F; Sami N; Naqvi AT; Islam A; Ahmad F; Imtaiyaz Hassan M
J Biomol Struct Dyn; 2017 Nov; 35(14):3194-3203. PubMed ID: 27748164
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Coumarin as Microtubule Affinity-Regulating Kinase 4 Inhibitor That Sensitize Hepatocellular Carcinoma to Paclitaxel.
Shen X; Liu X; Wan S; Fan X; He H; Wei R; Pu W; Peng Y; Wang C
Front Chem; 2019; 7():366. PubMed ID: 31179271
[TBL] [Abstract][Full Text] [Related]
6. Investigation of molecular mechanism of recognition between citral and MARK4: A newer therapeutic approach to attenuate cancer cell progression.
Naz F; Khan FI; Mohammad T; Khan P; Manzoor S; Hasan GM; Lobb KA; Luqman S; Islam A; Ahmad F; Hassan MI
Int J Biol Macromol; 2018 Feb; 107(Pt B):2580-2589. PubMed ID: 29079437
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
[TBL] [Abstract][Full Text] [Related]
8. Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.
Anwar S; Shamsi A; Shahbaaz M; Queen A; Khan P; Hasan GM; Islam A; Alajmi MF; Hussain A; Ahmad F; Hassan MI
Sci Rep; 2020 Jun; 10(1):10300. PubMed ID: 32587267
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-(2-(dimethylamino)ethoxy)benzohydrazide derivatives as prospective microtubule affinity regulating kinase 4 inhibitors.
Khan NS; Khan P; Inam A; Ahmad K; Yousuf M; Islam A; Ali S; Azam A; Husain M; Hassan MI
RSC Adv; 2020 May; 10(34):20129-20137. PubMed ID: 35520423
[TBL] [Abstract][Full Text] [Related]
10. Targeting inhibition of microtubule affinity regulating kinase 4 by Harmaline: Strategy to combat Alzheimer's disease.
Adnan M; Anwar S; DasGupta D; Patel M; Elasbali AM; Alhassan HH; Shafie A; Siddiqui AJ; Bardakci F; Snoussi M; Hassan MI
Int J Biol Macromol; 2023 Jan; 224():188-195. PubMed ID: 36257368
[TBL] [Abstract][Full Text] [Related]
11. Design and Development of Small-Molecule Arylaldoxime/5-Nitroimidazole Hybrids as Potent Inhibitors of MARK4: A Promising Approach for Target-Based Cancer Therapy.
Peerzada MN; Khan P; Khan NS; Avecilla F; Siddiqui SM; Hassan MI; Azam A
ACS Omega; 2020 Sep; 5(36):22759-22771. PubMed ID: 32954123
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, Structural Modification, and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors.
Voura M; Anwar S; Sigala I; Parasidou E; Fragoulidou S; Hassan MI; Sarli V
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):1052-1074. PubMed ID: 37470016
[TBL] [Abstract][Full Text] [Related]
13. Probing the Inhibition of Microtubule Affinity Regulating Kinase 4 by N-Substituted Acridones.
Voura M; Khan P; Thysiadis S; Katsamakas S; Queen A; Hasan GM; Ali S; Sarli V; Hassan MI
Sci Rep; 2019 Feb; 9(1):1676. PubMed ID: 30737440
[TBL] [Abstract][Full Text] [Related]
14. Structural and biochemical investigation of MARK4 inhibitory potential of cholic acid: Towards therapeutic implications in neurodegenerative diseases.
Anwar S; Shamsi A; Kar RK; Queen A; Islam A; Ahmad F; Hassan MI
Int J Biol Macromol; 2020 Oct; 161():596-604. PubMed ID: 32535203
[TBL] [Abstract][Full Text] [Related]
15. Identification and evaluation of bioactive natural products as potential inhibitors of human microtubule affinity-regulating kinase 4 (MARK4).
Mohammad T; Khan FI; Lobb KA; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2019 Apr; 37(7):1813-1829. PubMed ID: 29683402
[TBL] [Abstract][Full Text] [Related]
16. A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
Ahmed S; Mobashir M; Al-Keridis LA; Alshammari N; Adnan M; Abid M; Hassan MI
Front Oncol; 2022; 12():914032. PubMed ID: 35936719
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Microtubule Affinity Regulating Kinase 4 by Metformin: Exploring the Neuroprotective Potential of Antidiabetic Drug through Spectroscopic and Computational Approaches.
Ashraf GM; DasGupta D; Alam MZ; Baeesa SS; Alghamdi BS; Anwar F; Alqurashi TMA; Sharaf SE; Al Abdulmonem W; Alyousef MA; Alhumaydhi FA; Shamsi A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889524
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insights into MARK4 inhibition by galantamine toward therapeutic targeting of Alzheimer's disease.
Adnan M; DasGupta D; Anwar S; Shamsi A; Siddiqui AJ; Snoussi M; Bardakci F; Patel M; Hassan MI
Front Pharmacol; 2023; 14():1276179. PubMed ID: 37795023
[No Abstract] [Full Text] [Related]
19. Designing New Kinase Inhibitor Derivatives as Therapeutics Against Common Complex Diseases: Structural Basis of Microtubule Affinity-Regulating Kinase 4 (MARK4) Inhibition.
Naz F; Shahbaaz M; Bisetty K; Islam A; Ahmad F; Hassan MI
OMICS; 2015 Nov; 19(11):700-11. PubMed ID: 26565604
[TBL] [Abstract][Full Text] [Related]
20. Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4.
Anwar S; Khan S; Anjum F; Shamsi A; Khan P; Fatima H; Shafie A; Islam A; Hassan MI
J Cell Biochem; 2022 Feb; 123(2):359-374. PubMed ID: 34751461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
